This is a working overview of c-Met receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-01-31. Anything still debated is marked as such rather than presented as settled.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Marketed for research use in some regions. |
| Human clinical data | Limited or absent | Most evidence is from cell and animal studies. |
| Primary proposed pathway | HGF/c-Met signaling | Angiotensin IV-related activity also reported. |
| Common study models | Rodent neurons and behavioral tasks | Results may not translate directly to humans. |
| Key uncertainty | Bioavailability and brain exposure | Questions remain about absorption and target engagement. |
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
== Clinical Significance == In diseases related to the cartilage, the territorial matrix undergoes structural and material changes, leading to degradation of the joints, like in the case of osteoarthritis. Osteoarthritis occurs when the proteoglycans and collagen fibers degrade and become disorganized. Consequently, the decreased mechanical support makes chondrocytes more vulnerable to damage. Matrix-degrading enzymes including matrix metalloproteinases (MMPs) target the region which can accelerate cartilage degradation. Attempts to restore a functional territorial matrix is a particular area of interest in tissue engineering and cartilage repair, since its structure significantly contributes to optimal mechanical and biochemical behavior. Studies on biomimetic proteoglycans, which mimic the natural existing component of the ECM, and their effect on neighboring cartilage regions have shown promising results for strengthening cartilage with osteoarthritis. Additionally, biomaterials designed to mimic native composition and mechanical properties of cartilage, especially those with synthetic proteoglycans or collagen, have shown experimental promise. In combination with these structures, the durability of engineering cartilage may be enhanced by regenerating the territorial matrix and could improve integration with native tissue.
August Wilhelm joined the conservative nationalist veterans group Der Stahlhelm (English: "The Steel helmet"). In the following years he had increasing contact with the NSDAP. He joined the Nazi Party on 1 April 1930, whereupon he received the low membership number 24, for symbolic reasons. In November 1931, he was accepted into the paramilitary Sturmabteilung (SA) with the rank of Standartenführer. His involvement with the NSDAP and his adoration of Adolf Hitler made August Wilhelm often the subject of mockery by the left-wing press (who gave him the nickname Braunhemdchen Auwi, or "Auwi the Little Brown Shirt"), politicians (French Ambassador André François-Poncet called him Hanswurst "Hans the Brown Sausage") and from the National Socialists themselves (Joseph Goebbels referred to him as a "good-natured but slightly gormless boy"). As a representative of the erstwhile Hohenzollern dynasty, August Wilhelm was deliberately used by the party to gain votes in elections: he was elected as its lead candidate for the Landtag of Prussia in April 1932, and retained his seat until the Landtag's dissolution in October 1933. At the same time, he was appointed an election speaker alongside Hitler, whom he accompanied on flights across Germany. Through his appearances at the party's mass rallies, he addressed himself to sections of the population that were lukewarm towards National Socialism and convinced them "that Hitler was not a threat, but a benefactor of the German people and the German Empire".
=== EC 2.9: selenium transferases === EC 2.9 includes enzymes that transfer selenium-containing groups. This category only contains two transferases, and thus is one of the smallest categories of transferase. Selenocysteine synthase, which was first added to the classification system in 1999, converts seryl-tRNA(Sec UCA) into selenocysteyl-tRNA(Sec UCA).
Sources: en.wikipedia.org
== Injectable materials == Many different materials have been used as perianal injectable bulking agents. The ideal injectable or implantable material would be biocompatible, non-migratory, non-allergenic, non-carcinogenic and non-immunogenic (and therefore induce a minimal inflammatory and fibrotic reaction). The material should also be easy to inject. The particles should be greater than 80 μm in diameter in order to prevent migration away from the injection site. On the other hand, materials with particles small enough to be used in small caliber needles may be desirable, in order to leave a smaller needle track, which may reduce the chance of leakage of the material via the needle track. Alternatively, some materials are shape-retaining porous hydrogels with no particles. The ideal material should produce an improvement in continence not only in the short term, but in the long term, and repeated procedures should not be necessary. Technically, most materials are particles suspended in a carrier (excipient) solution, which is usually a biodegradable gel. It is not known which of the available materials is the best.
The first fossil specimen of the dinosaur later named Sinosauropteryx prima was uncovered in August 1996 by Li Yumin. Yumin was a farmer and part-time fossil hunter who often prospected around Liaoning Province to acquire fossils to sell to individuals and museums. Yumin recognized the unique quality of the specimen, which was separated into two slabs, and sold the slabs to two separate museums in China: the National Geological Museum in Beijing, and the Nanjing Institute of Geology and Paleontology. The director of the Beijing museum, Ji Qiang, recognized the importance of the find, as did visiting Canadian palaeontologist Phil Currie and artist Michael Skrepnick, who became aware of the fossil by chance as they explored the Beijing museum's collections after leading a fossil tour of the area during the first week of October, 1996. Currie recognized the significance of the fossil immediately. As The New York Times quoted him, "When I saw this slab of siltstone mixed with volcanic ash in which the creature is embedded, I was bowled over." When originally described, the authors named Sinosauropteryx, meaning "Chinese Reptilian Wing". Chinese authorities initially barred photographs of the specimen from publication. However, Currie brought a photograph to the 1996 meeting of the Society of Vertebrate Paleontology at the American Museum of Natural History in New York, causing crowds of palaeontologists to gather and discuss the new discovery.
=== Autoimmune disease === Multiple autoimmune disorders are caused by the binding of IgG to self antigens. Since FcRn extends IgG half-life in the circulation, it can also confer long half-lives on these pathogenic antibodies and promote autoimmune disease.
== Reactions == As a lactone, GBL is hydrolyzed under basic conditions, for example in a sodium hydroxide solution into sodium gamma-hydroxybutyrate, the sodium salt of gamma-hydroxybutyric acid. In acidic water, a mixture of the lactone and acid forms exists in an equilibrium. These compounds then may go on to form the polymer poly(4-hydroxybutyrate) as well as the dimer 1,6-Dioxecane-2,7-dione. When treated with a non-nucleophilic base, such as lithium diisopropylamide, GBL undergoes deprotonation of the alpha carbon atom to the carbonyl.
Sources: en.wikipedia.org
== Life and work == Emanuel Gil-Av was born 1916 in Pensa of Tzarist Russia. After the death of his father, a physician, the family moved first to Central Europe and in 1928 to Tel-Aviv, Israel, where Gil-Av attended High School. Gil-Av studied petroleum chemistry at the University of Strasbourg. In 1940 he escaped the German occupation to England where he worked at first in the chemical laboratory of Chaim Weizmann, followed by the Petrochemical Ltd. in Manchester. After World War II, he moved to Palestine and he joined the Daniel Sieff Institute in Rehovot which was later on to become the Weizmann Institute of Science. In 1951 he earned his PhD under the supervision of Ernst David Bergmann. In his study of oil shale deposits, Gil-Av developed complex-forming stationary phases employing silver(I) ions for selective olefin separations by gas chromatography (GC). In co-operation with the centre of peptide chemistry at the Weizmann Institute of Science, he developed methods of the gas-chromatographic resolution of racemic α-amino acids. By coating a glass capillary column with the chiral stationary phase (CSP) N-trifluoroacetyl-L-isoleucine lauryl ester, Gil-Av et al. carried out in 1966 the first gas-chromatographic enantioseparation of racemic amino acids as N-trifluoroacetyl-O-alkyl derivatives. Many racemic compounds, amenable for enantioselective interaction via hydrogen bonding with the CSP, could be analytically enantioseparated by GC.
Under the terms of his 2011 employment agreement, McCord received $529,994 in direct compensation as well as a 50-cent commission on every bottle of Protandim sold. McCord served as LifeVantage's Chief Scientific Officer from June 2011 until September 2012, and then became a member of its science advisory board. LifeVantage announced McCord's retirement in June 2013. Under the terms of the separation agreement, McCord was to receive a payment of $1.7 million from the company. In January 2014, McCord was replaced by Shawn Talbott (developer of CortiSlim), who served as the company's chief science officer until being relieved of his duties in June 2015 and replaced in August 2015 by Natalie Chevreau, who was hired as the company's senior vice president of research and development and is credited with the invention of the company's TruScience skin care product.
== Analytical method for residues in livestock == In cattle and swine tissue, it was found in 2007 that a procedure for the analysis of ractopamine residues in liver or muscle can be performed by high performance liquid chromatography (HPLC) with fluorescence detection. The confirmatory method include reversed-phase HPLC/electrospray ionization triple tandem quadrupole mass spectrometry. The limit of quantification of the drug using this LC/MS instrument was shown to be 1 ng/g (1 ppb). In cattle, a 2018 Chinese study promoted the use of hair as an indelible test of feed containing ractopamine.
==== Bill Clinton ==== Hitchens became increasingly disenchanted by the presidency of Bill Clinton, accusing him of being a rapist, a liar, and war criminal. Hitchens said the missile attacks by Clinton on Sudan constituted a war crime. Hitchens criticized Clinton for his pardon of Marc Rich and others who had donated to Clinton, overseeing the execution of Ricky Ray Rector, his relationships with Monica Lewinsky and Gennifer Flowers. In 1999, Hitchens became involved in the Impeachment trial of Bill Clinton when Hitchens friend and Clinton adviser Sidney Blumenthal said under oath during a deposition that he had never described Monica Lewinsky as a stalker. In response to Blumenthal's testimony Hitchens submitted a sworn affidavit saying that he had in fact described Lewinsky as a stalker at a lunch with Hitchens and his wife.
=== Megaloblastic anemia === Neutrophil hypersegmentation is one of the earliest, most sensitive and specific signs of megaloblastic anemia (mainly caused by hypovitaminosis of vitamin B12 & folic acid). Nuclear hypersegmentation of DNA in neutrophils strongly suggests megaloblastosis when associated with macro-ovalocytosis. If megaloblastosis is suspected, a formal lobe count/neutrophil (i.e. lobe index) above 3.5% can be obtained. Hypersegmentation persists for an average of 14 days after institution of specific therapy.
Sources: en.wikipedia.org
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.
Preclinical research has focused on synaptic growth, cognitive performance in animals, and HGF/c-Met signaling. These are experimental findings, not established treatments.
Legality varies by country and intended use. It is commonly sold as a research chemical, and sales for human consumption may be restricted. Local regulations should be checked.
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.